Skip to content

    Recently Viewed


      Our Company

      The Janssen Pharmaceutical Companies of Johnson & Johnson issues its 2019 Janssen U.S. Transparency Report

      Share Article
      share to

      Titusville, NJ – (April 8, 2020) – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson issued its 2019 Janssen U.S. Transparency Report, available at

      Scott White, Company Group Chairman, North America Pharmaceuticals for Johnson & Johnson, issued the following statement on the release of the report:

      Thanks to an open and competitive marketplace, the U.S. health system delivers innovative treatment choices and earlier access to groundbreaking medicines, yet out-of-pocket costs continue to be an issue for many people.

      At Janssen, we’re helping lead the way to a stronger health system that works better for patients by supporting pro-competition policy solutions and affordable access to our innovations. As our 2019 Janssen U.S. Transparency Report shows, the average net price of our medicines continues to fall and we invested $39.4 billion in R&D over the last five years. That investment is bringing transformational medical advances for patients and is contributing to achievements like the major drop in cancer rates here in the U.S. over the last 25 years. Results like these highlight the urgency of reducing patients’ out-of-pocket costs and driving innovation that enables us to meet future unmet needs.

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.